Cargando…

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the treatment of hematological malignancies, but the systemic toxicity and complex manufacturing process of current autologous CAR-T cell therapy hinder its broader applications. Universal CAR-T cells have been dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xin, Tianqing, Cheng, Li, Zhou, Chuchao, Zhao, Yimeng, Hu, Zhenhua, Wu, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866962/ https://www.ncbi.nlm.nih.gov/pubmed/35223491 http://dx.doi.org/10.3389/fonc.2022.809754

Ejemplares similares

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Hurdles to breakthrough in CAR T cell therapy of solid tumors
por: Marofi, Faroogh, et al.
Publicado: (2022)

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
por: Stadtmauer, Edward, et al.
Publicado: (2017)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
por: Dehbashi, Moein, et al.
Publicado: (2021)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma
por: Scarfò, Irene, et al.
Publicado: (2019)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
por: Vanhooren, Jolien, et al.
Publicado: (2023)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
por: Rossig, Claudia, et al.
Publicado: (2018)

CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2022)

Advances in CAR T cell immunotherapy for paediatric brain tumours
por: Rao, Padmashree, et al.
Publicado: (2022)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Umbilical cord blood: A promising source for allogeneic CAR-T cells
por: Liu, Dian-Dian, et al.
Publicado: (2022)

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
por: Nan, Feifei, et al.
Publicado: (2022)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

CAR-T cell therapy: current limitations and potential strategies
por: Sterner, Robert C., et al.
Publicado: (2021)

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
por: Petersen, Christopher T., et al.
Publicado: (2019)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective
por: Sievers, Savannah, et al.
Publicado: (2020)

CAR Chase: Where Do Engineered Cells Go in Humans?
por: Krebs, Simone, et al.
Publicado: (2020)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover, Maya, et al.
Publicado: (2021)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma
por: Long, Cheng, et al.
Publicado: (2021)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

A Metabolism Toolbox for CAR T Therapy
por: Xu, Xuequn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v2scevvu1drlepdp9bboljrnas